Recent advances of molecular targeted therapy in small cell lung cancer

VernacularTitle:小细胞肺癌分子靶向治疗研究进展
Author: Bing LIU
Publication Type:Journal Article
Keywords: Carcinoma,small cell; Lung neoplasms; Molectdes,targeted,therapy
From: Journal of International Oncology 2009;36(7):524-527
CountryChina
Language:Chinese
Abstract: Molecular targeted agents for small cell lung cancer have been introduced in great many clinical trials in recent years. The classes of targeted agents include antiangiogenic agents,growth factor receptor inhibitors,Bcl-2 inhibitors,SCR kinase inb.ibitors, recombinant molecules N-901 and inhibitors of the sonic hedgehog signaling pathway. The class of antiangiogenic agents,including bevacizumab and thalidomide,is be-ing evaluated in phase Ⅱ and Ⅲ trials. The tyrosine and Scr kinase inhibitors are being evaluated in phase Ⅰ and Ⅱ trials. The recombinant molecule, N-901 is undergoing phase Ⅱ testing in patients with relapsed small cell lung cancer. The other pathways undergoing evaluation for the development of pharmacologic agents include inhibiturs of bcl-2 and sonic hedgehog signaling,which are being tested in the earliest phases of clinical evalua-tion. Primary data shows small cell lung cancer is not sensitive to targeted therapy and further studies are re-quested.